Epigen
This article was originally published in The Gray Sheet
Executive Summary
Expects to begin clinical trials of an in vitro blood test designed to measure the effectiveness of cancer treatment "in the first half of 1993," according to a recent press release. The test measures the level of human carcinoma antigen (HCA) in the bloodstream. A U.S. patent application was filed in February for the test and two other products: an in vivo imaging agent designed to identify a tumor site with a radioactive label and a cancer vaccine which "uses proprietary anti-idiotypic monoclonal antibodies to act like purified HCA and activate an immune system response to treat malignant tumors." Epigen plans to file an investigational new drug application for the imaging agent in the second quarter.